ERBB2 and breast cancer: The KATHERINE trial revealed that adjuvant T-DM1 greatly increased the 3-year invasive disease-free survival (iDFS) rate of patients with HER2-positive BC who did not achieve pCR who had received neoadjuvant therapy.